PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer ES-SCLC

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT06769126

Study #:
STUDY00162293

Start Date:
Mar 18, 2026

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06769126

View Complete Trial Details & Eligibility at ClinicalTrials.gov